S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer|
|CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas|
|Zeldes & Haeggquist, LLP Continues Investigation of CytRx Corporation|
|Oral Presentation of CytRx’s Aldoxorubicin Phase 2b Clinical Trial in Soft Tissue Sarcoma Highlighted in The Lancet Oncology|
|Federman & Sherwood Investigates CytRx Corporation for Possible Violations of Federal Securities Laws|
|CytRx Updates Presentation Time at Aegis 2014 Healthcare & Technology Conference|
|CytRx to Present at Upcoming Investor Conferences in New York City and Las Vegas|
|CytRx Reports 2014 Second Quarter Financial Results|
|Former Louisiana Attorney General and KSF Announce Appointment as Lead Counsel in CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire for More Information -- CYTR|
|CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer|
Click above to view more mutual fund data and stats for cytr - CytRx Corp.